You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ)擬投資引進PD-1和CTLA-4項目
格隆匯 06-22 16:16

格隆匯6月22日丨貝達藥業(300558.SZ)公佈,2020年6月20日,公司第三屆董事會第八次會議審議通過《關於公司投資引進PD-1和CTLA-4項目的議案》。公司與AgenusInc.(NASDAQ:AGEN,以下簡稱“Agenus”)達成合作,以自有資金支付Agenus 1500萬美元的首付款,同時通過貝達投資(香港)有限公司(以下簡稱“貝達投資”)以2000萬美元現金認購Agenus增發的股份,貝達藥業取得在中國(包括香港、澳門和台灣,下同)區域內單用或聯用治療除膀胱內給藥外的所有腫瘤學和非腫瘤學適應症的獨家開發並商業化Balstilimab(PD-1抗體)和Zalifrelimab(CTLA-4抗體)的權利。

Balstilimab和Zalifrelimab是Agenus所有的腫瘤免疫單克隆抗體。Balstilimab是一種免疫檢查點抑制劑,靶向於T細胞上的程序性死亡受體1(PD1)的全人源單克隆抗體。Zalifrelimab是一種靶向於T細胞表面表達的細胞毒性T淋巴細胞相關抗原4(CTLA-4)的全人源單克隆抗體。PD-1和CTLA-4均是腫瘤免疫治療方向的熱門且已成藥靶點。

目前,Agenus正在對Balstilimab和Zalifrelimab展開Ⅱ期臨牀試驗,計劃在2020年向美國FDA遞交Balstilimab單一療法以及Balstilimab和Zalifrelimab二者聯用在難治性宮頸癌適應症上的上市申請。此次引進Balstilimab和Zalifrelimab將進一步充實公司研發管線,彌補公司在大分子創新藥領域的短板。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account